2023-07-07 08:22:24
A new drug created by the Japanese pharmaceutical company Eisai will be the key to slowing down the effects of Alzheimer’s. Lecanemab, with the trade name Leqembi, has been approved this Thursday by the United States Food and Drug Administration (FDA) for use once its efficacy has been confirmed.
Although the FDA had already approved the drug last January, there was still one last clinical trial to give complete satisfaction. According to Teresa Buracchio, acting director of the Office of Neuroscience at the FDA’s Center for Drug Evaluation and Research, recent studies show that it is a safe treatment.
LOOK: Alzheimer’s: Could a tear diagnose this disease in the future?
Alzheimer’s is a neurodegenerative disease that slowly erases memory and the ability to do tasks. But according to data given by the FDA, the last study carried out on 1800 patients would have shown a significant reduction in cognitive deterioration.
Although many have doubted the possible side effects. The drug would be administered intravenously, and many have commented on whether it would cause inflammation and bleeding in the brain; a condition called aria that occurs in several patients. The FDA admitted that Leqembi might cause some of these side effects, with deadly results.
At the moment, it has been recommended not to prescribe Leqembi in patients who use anticoagulant medication, since this would increase the risk of suffering brain haemorrhages. It should be applied, above all, in patients with mild cognitive impairment and in early stages of Alzheimer’s disease.
AgroFest
1688726726
#alzheimerunitedstatesdrug #approves #medicine #treat #Alzheimers #SCIENCE
